Article
Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy.
Molecular therapy : the journal of the American Society of Gene Therapy - 1 Jun 2000
Aoki K, Akyürek L M, San H, Leung K, Parmacek M S, Nabel E G, Nabel G J
Abstract excerpt
Gene transfer of Fas ligand (CD95L) using adenoviral vectors has been shown to generate apoptotic responses and potent inflammatory reactions that can be used to induce the regression of malignancies in vivo, but these vectors also cause significant hepatotoxicity that may limit their clinical utility. Here we describe an adenoviral vector encoding CD95L with restricted gene expression that reduces its toxicity...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.